Streetbeat News

Analyst Ratings

RF

Regions Finl (NYSE:RF) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, and 4 indifferent ratings. The company's average 12-month price target is $19.58, a 16.68% decrease from the previous average of $23.50.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 3:00 pm

PSX

Phillips 66's (NYSE:PSX) short percent of float has risen 3.7% since its last report, with 9.95 million shares sold short, which is 2.52% of all regular shares available for trading. It would take traders 2.7 days to cover their short positions on average. The company's short interest is less than its peer group average of 9.50%.

Portfolio Pulse from Benzinga Insights

October 23, 2023 | 3:00 pm

TIXT

Barclays analyst Ramsey El-Assal has maintained an Equal-Weight rating on TELUS Intl (NYSE:TIXT) but lowered the price target from $11 to $9.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:59 pm

TIGO

HSBC has downgraded Millicom's stock from Buy to Hold, leading to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:56 pm

SYY

Barclays analyst Jeffrey Bernstein has maintained an Overweight rating on Sysco (NYSE:SYY) but lowered the price target from $86 to $77.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:55 pm

AXP

RBC Capital analyst Jon Arfstrom has maintained an 'Outperform' rating on American Express (NYSE:AXP), but lowered the price target from $190 to $185.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:55 pm

RVNC

Barclays analyst Balaji Prasad has maintained an Overweight rating on Revance Therapeutics (NASDAQ:RVNC) but lowered the price target from $40 to $35.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:53 pm

RF

Barclays analyst Jason Goldberg has maintained an Equal-Weight rating on Regions Financial Corp (NYSE:RF) but lowered the price target from $23 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:50 pm

AMAM

RBC Capital analyst Brian Abrahams has maintained an Outperform rating on Ambrx Biopharma (NASDAQ:AMAM) and raised the price target from $29 to $33.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:49 pm

RXT

Barclays analyst Ramsey El-Assal has maintained an Underweight rating on Rackspace Tech (NASDAQ:RXT) and lowered the price target from $2 to $1.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 2:48 pm